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Foreword 
The use of biopsy to study airway inflammation 
Airway inflammation is a characteristic feature of asthma. 
The typical components of chronic inflammation are loss of 
surface epithelium, a thickening of the reticular layer of the 
sub-epithelial basement membrane (BM) (l), and increased 
numbers of eosinophils, mast cells and T lymphocytes in the 
airway mucosa; increased numbers of eosinophils are 
commonly found even in patients with mild disease, and 
the number of these cells is correlated with disease severity 
(2). Cellular infiltration is promoted by increased expres- 
sion of a number of cytokines, the profile of which is 
usually consistent with a T-helper 2 (TH,) phenotype, with 
increased expression of interleukin (IL)-4 and IL-S (3). 
Excessive mucus is produced by epithelial goblet cells, and 
increased vascular permeability also occurs, resulting in 
mucosal oedema. The airway is narrowed both by the 
oedema and by hypertrophy of bronchial smooth muscle. 
Severe steroid-dependent asthmatics may have a different 
type of inflammation to that in mild to moderate asthma, 
with greater neutrophilic infiltration; in some of these 
patients, eosinophilia is absent (4). 
Airway remodelling, which is usually consequent to 
chronic inflammation (1) describes a more persistent 
process of structural change that is typical of established 
and possibly under-treated asthma; this may be triggered by 
damage to the bronchial epithelium (5). 
By taking biopsies of bronchial tissue, inflammatory 
changes can be directly observed using electron microscopy 
(EM). This allows assessment of the mucosal structure, 
including the epithelium, BM, lamina propria, and vascu- 
lature; this information cannot be gained from bronchoal- 
veolar lavage (BAL) or induced sputum samples. EM also 
allows study of inflammatory cells such as eosinophils, mast 
cells and plasma cells. By using high-resolution scanning 
EM, cell surfaces can be studied in fine detail. Confocal 
microscopy may also be useful. Biopsy samples can be 
subjected to freeze-fracture to study the integrity of the 
tight junction between epithelial cells, through which 
allergen particles may gain access to antibody presenting 
cells in the mucosa. 
Other techniques are used to process and analyse biopsy 
samples to generate more information about the underlying 
cellular and molecular abnormalities present in patients 
with asthma. One of the most frequently used methods is 
immunohistochemistry; this entails staining the tissue with 
conjugated monoclonal or polyclonal antibodies, so that 
the inflammatory cells can be classified according to the cell 
surface antigens that they express, e.g. EGl+ and EG2+ 
for eosinophils (6). This treatment colours the cells so that 
they can easily be identified and counted by microscopy; 
this method also allows the activation status of certain cells 
to be determined. Another widely used tool is in situ 
hybridization, which is used to detect the presence of 
intracellular mRNA that codes for synthesis of proteins 
such as interleukins and interferon (7,8). 
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The practice of bronchial biopsy is now so widespread 
that there is a need to standardize biopsy methods, 
including excision and processing of the sample, fixing 
and sectioning it, and counting cells (or otherwise analysing 
the histology). Although the variability introduced by 
differences in biopsy methods is small when compared with 
the heterogeneity of asthma patients, standardization 
would simplify interpretation of study results; until this is 
achieved, it is important that investigators report in detail 
the methods used to process and analyse the biopsy. The 
variability in baseline counts of inflammatory cells between 
patients, and diurnal variation in levels of inflammatory 
markers, can be addressed through rigorous study design, 
as described in the second article of this supplement (9). 
Bronchoscopy is acknowledged to carry a medical risk 
and the invasiveness of the procedure may discourage 
patients (or volunteers) from participating in biopsy 
studies; the risk/benefit ratio of the procedure has greatly 
improved, however, and no longer limits the use of biopsy. 
An exception to this is transbronchial biopsy which is used 
for sampling the lower airway and is associated with a 
higher risk of bleeding and more serious complications. 
Biopsy may cause epithelial damage, which complicates the 
interpretation of studies measuring epithelial fragility in 
asthmatic patients. 
BAL is frequently performed at the same time as 
bronchial biopsy, and is useful for studying the activation 
status of inflammatory cells. The disadvantage of BAL is 
that it is a dilute sample, largely derived from the alveolar 
compartment; significant changes in the number of certain 
inflammatory cells may be difficult to detect. The propor- 
tion of the sample that derives from the airways can be 
increased by reducing the lavage volume. 
Induction of sputum provides a more concentrated 
source of airway secretions than BAL, deriving mainly 
from the large airways. This procedure can be performed 
many times in the same subject and is very reproducible. 
However, sputum is a complex biological sample; measure- 
ment of the component of the fluid phase needs careful 
validation, and the sample is prone to degradation if not 
carefully handled and stored. The procedure provides no 
direct information on the structure of the airway. 
Inflammation can also be assessed directly from the 
macroscopic appearance of the airway surface during 
bronchoscopy. Other methods are being developed that 
may help to quantify or assess inflammation in the lung, 
including exhaled nitric oxide and exhaled breath con- 
densates. However, until these procedures are fully 
validated for a wide range of clinical applications, bronchial 
biopsy will remain the best procedure for the sampling of 
airway tissue and for the direct study of inflammatory 
changes. 
The papers in this issue of Respiratory Medicine form the 
proceedings of a Biopsy Workshop held in Copenhagen in 
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November 1999, and cover two main topics. The first is the 
optimization of biopsy assessments in the context of clinical 
study design. The two papers review ways in which 
elements of protocol design can improve the productivity 
of the biopsy results, and present recommendations on the 
selection of inflammatory markers that may be monitored 
in assessments of drug treatment for asthma. 
The second topic is the effect of treatment on the 
inflammatory component of asthma. Three papers review 
biopsy studies and other investigations that have shed light 
on the anti-inflammatory profiles of inhaled corticosteroids, 
long-acting &agonists, and the combination of salmeterol 
with inhaled corticosteroids. These papers provide a timely 
survey of how the application of bronchial biopsy 
techniques has allowed an improved evaluation of how 
modern drug therapies modify the cellular and mechanistic 
processes of asthma. 
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